Bcl-xL expression levels in tumor samples correlate with higher tumor grades and shorter relapse-free survival in glioma (Ita et al., 2022), chondrosarcoma (de Jong et al., 2018), tongue carcinoma (Zhang et al., 2014), triple-negative breast cancer (Skov et al., 2022), and melanoma (Gabellini et al., 2018). The gene discussed is BCL2L1; the disease is triple-negative breast carcinoma.